PSA screening

New prostate cancer risk score could help guide screening decisions

Genetic risk model “might play a role in guiding decisions about whether and when to screen for prostate cancer,” say experts

Photo
Source: Pixabay/Maialisa

A new score for predicting a man’s genetic risk of developing aggressive prostate cancer could help guide decisions about who to screen and when, say researchers in The BMJ today. Prostate cancer is the most frequently diagnosed cancer in males in developed countries, with over a million new cases and over 300,000 associated deaths estimated worldwide in 2012.

Screening for prostate specific antigen or PSA (a cancer indicator) can lead to early detection and potentially life saving treatment. But many guidelines do not endorse universal screening due to concerns about elevated PSA in men without cancer and overtreatment for men who have cancer but might never develop aggressive disease.

Ideally, physicians would identify and screen patients at high risk of developing aggressive prostate cancer at a young age, but a practical clinically useful tool to predict age of onset is not yet available.

It can be calculated once, long before onset of prostate cancer, and substantially inform the decision of whether he should undergo screening

So researchers used data from an international study collaboration (the PRACTICAL consortium) to develop and test a genetic tool to predict age of onset of aggressive prostate cancer and to guide decisions of who to screen and at what age. They analysed over 200,000 gene variants (known as single nucleotide polymorphisms or SNPs) from 31,747 men of European ancestry with and without prostate cancer and identified 54 associated with increased risk of prostate cancer. These polymorphisms were incorporated into a survival analysis to estimate their effects on age at diagnosis of aggressive prostate cancer in the form of a hazard score. The final model was then applied to data from an independent clinical trial of 6,411 men to test (“validate”) prediction of survival, free from prostate cancer. 

In the independent validation, the hazard score was a highly significant predictor of age at diagnosis of aggressive cancer. Men in the top 2% of the score had an almost three-fold greater relative risk for aggressive prostate cancer compared with men with average risk. And the researchers say that, as the score is representative of a man’s fixed genetic risk, “it can be calculated once, long before onset of prostate cancer, and substantially inform the decision of whether he should undergo screening.” They point to some study limitations, and say they cannot rule out the possibility that other unmeasured factors may have influenced their results. Nevertheless, they say these results “add to existing data as further evidence that genetic features can predict risk of prostate cancer.” They add that the score “is a relatively inexpensive assessment of an individual man’s age specific risk and provides objective information on whether a given patient might benefit from PSA screening.”


Source: The BMJ

11.01.2018

Read all latest stories

Related articles

MRI - prostate cancer screening for the future?

A screening method that combines a traditional PSA test with an MRI detects a significantly greater number of prostate cancer cases and improves diagnostic accuracy. The study was conducted as part…

Antibiotic stewardship

Screening with multiplexed kits

Antibiotic stewardship is becoming a critical concern in hospitals as antibiotic resistance spreads globally and some organisms become resistant to antibiotics of last resort. Molecular diagnostics…

Research

3D mammography detected 34% more breast cancers in screening

After screening 15 000 women over a period of five years, a major clinical study in Sweden has shown that 3D mammography, or breast tomosynthesis, detects over 30% more cancers compared to…

Related products

Immunochemistry

Beckman Coulter - phi (Prostate Health Index)

Beckman Coulter, Inc.

MRT Coils

NORAS Uni-Lift Prostate Intervention Device

NORAS MRI products GmbH